The Securities and Exchange Commission (“Commission”) announced the temporary suspension, pursuant to Section 12(k) of the Securities Exchange Act of 1934 (the "Exchange Act"), of trading in the securities of Signpath Pharma, Inc. (“SGTH”) (CIK No. 0001455694), of Sandy, Utah at 9:30 a.m. EDT on April 16, 2020, and terminating at 11:59 p.m. EDT on April 29, 2020.

The Commission temporarily suspended trading in the securities of SGTH due to questions and concerns regarding the accuracy and adequacy of publicly available information concerning SGTH, including a public claim made by SGTH on March 17, 2020, regarding SGTH’s development of a COVID-19 treatment, together with a lack of current financial information in the marketplace.

The Commission cautions broker-dealers, shareholders, and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company.

Further, brokers and dealers should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. If any broker or dealer has any questions as to whether or not it has complied with the rule, it should not enter any quotation but immediately contact the staff in the Division of Trading and Markets, Office of Interpretation and Guidance, at (202) 551-5777. If any broker or dealer is uncertain as to what is required by Rule 15c2-11, it should refrain from entering quotations relating to SGTH’s securities until such time as it has familiarized himself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action.

If any broker, dealer or other person has any information that may relate to this matter, they should immediately contact Celeste A. Chase, Assistant Regional Director, at (212) 336-0049, or Jason R. Berkowitz, Assistant Regional Director, at (305) 982-6309. The Commission appreciates the assistance of the Financial Industry Regulatory Authority (FINRA).